• Lee MJ, Leong MW, Rustagi A, Beck A, Zeng L, Holmes S, Qi LS, Blish CA. SARS-CoV-2 escapes direct NK cell killing through Nsp1-mediated downregulation of ligands for NKG2D. Cell Rep. 2022 Dec 27;41(13):111892. doi: 10.1016/j.celrep.2022.111892. Epub 2022 Dec 12. PMID: 36543165; PMCID: PMC9742201.
• Cable J, Balachandran S, Daley-Bauer LP, Rustagi A, Antony F, Frere JJ, Strampe J, Kedzierska K, Cannon JL, McGargill MA, Weiskopf D, Mettelman RC, Niessl J, Thomas PG, Briney B, Valkenburg SA, Bloom JD, Bjorkman PJ, Iketani S, Rappazzo CG, Crooks CM, Crofts KF, Pohlmann S, Krammer F, Sant AJ, Nabel GJ, Schultz-Cherry S. Viral immunity: Basic mechanisms and therapeutic applications-a Keystone Symposia report. Ann N Y Acad Sci. 2023 Mar;1521(1):32-45. doi: 10.1111/nyas.14960. Epub 2023 Jan 30. PMID: 36718537.
• Choi SS, van Unen V, Zhang H, Rustagi A, Alwahabi SA, Santos AJM, Chan JE, Lam B, Solis D, Mah J, Roltgen K, Trope W, Guh-Siesel A, Lin Z, Beck A, Edwards C, Mallajosyula V, Martin BA, Dunn JCY, Shrager J, Baric RA, Pinsky B, Boyd SD, Blish CA, Davis MM, Kuo CJ. Organoid modeling of lung-resident immune responses to SARS-CoV-2 infection. Res Sq. 2023 May 5:10.21203/rs.3.rs-2870695/v1. doi: 10.21203/rs.3.rs-2870695/v1. PMID: 37205380; PMCID: PMC10187413.
• Carroll TD, Wong T, Morris MK, Di Germanio C, Ma ZM, Stone M, Ball E, Fritts L, Rustagi A, Simmons G, Busch M, Miller CJ. Administration of vaccine-boosted COVID-19 convalescent plasma to SARS-CoV-2 infected hamsters decreases virus replication in lungs and hastens resolution of the infection despite transiently enhancing disease and lung pathology. bioRxiv. 2023 Aug 23:10.1101/2023.08.22.553458. doi: 10.1101/2023.08.22.553458. PMID: 37662344; PMCID: PMC10473650.
• Carroll TD, Wong T, Morris MK, Di Germanio C, Ma ZM, Stone M, Ball E, Fritts L, Rustagi A, Simmons G, Busch M, Miller CJ. Vaccine-Boosted CCP Decreases Virus Replication and Hastens Resolution of Infection Despite Transiently Enhancing Disease in SARS-CoV-2-Infected Hamsters. J Infect Dis. 2024 Jan 12:10.1093/infdis/jiad568. doi: 10.1093/infdis/jiad568. Epub ahead of print. PMID: 38213276.
• Westberg M, Su Y, Zou X, Huang P, Rustagi A, Garhyan J, Patel PB, Fernandez D, Wu Y, Hao C, Lo CW, Karim M, Ning L, Beck A, Saenkham-Huntsinger P, Tat V, Drelich A, Peng BH, Einav S, Tseng CK, Blish C, Lin MZ. An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations. Sci Transl Med. 2024 Mar 13;16(738):eadi0979. doi: 10.1126/scitranslmed.adi0979. Epub ahead of print. PMID: 38478629.
• Wu TT, Travaglini KJ, Rustagi A, Xu D, Zhang Y, Andronov L, Jang S, Gillich A, Dehghannasiri R, Martinez-Colon GJ, Beck A, Liu DD, Wilk AJ, Morri M, Trope WL, Bierman R, Weissman IL, Shrager JB, Quake SR, Kuo CS, Salzman J, Moerner WE, Kim PS, Blish CA, Krasnow MA. Interstitial macrophages are a focus of viral takeover and inflammation in COVID-19 initiation in human lung. J Exp Med. 2024 Jun 3;221(6):10.1084/jem.20232192. doi: 10.1084/jem.20232192. Epub 2024 Apr 10. PMID: 38597954; PMCID: PMC11009983.
• Salzman GS, Zhang S, Fernandez CG, Arac D, Koide S. Specific and direct modulation of the interaction between adhesion GPCR GPR56/ADGRG1 and tissue transglutaminase 2 using synthetic ligands. Sci Rep. 2020 Oct 9;10(1):16912. doi: 10.1038/s41598-020-74044-6. PMID: 33037308; PMCID: PMC7547085.
• Khodadoust MS, Olsson N, Chen B, Sworder B, Shree T, Liu CL, Zhang L, Czerwinski DK, Davis MM, Levy R, Elias JE, Alizadeh AA. B-cell lymphomas present immunoglobulin neoantigens. Blood. 2019 Feb 21;133(8):878-881. doi: 10.1182/blood-2018-06-845156. Epub 2018 Dec 13. PMID: 30545830; PMCID: PMC6384186.
• Shree T, Li Q, Glaser SL, Brunson A, Maecker HT, Haile RW, Levy R, Keegan THM. Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020 May 20;38(15):1664-1675. doi: 10.1200/JCO.19.01937. Epub 2020 Feb 21. PMID: 32083991; PMCID: PMC7238489.
• Haebe S, Shree T, Sathe A, Day G, Czerwinski DK, Grimes SM, Lee H, Binkley MS, Long SR, Martin B, Ji HP, Levy R. Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma. Blood. 2021 May 27;137(21):2869-2880. doi: 10.1182/blood.2020009855. PMID: 33728464; PMCID: PMC8160505.
• Shree T, Shankar V, Lohmeyer JJK, Czerwinski DK, Schroers-Martin JG, Rodriguez GM, Beygi S, Kanegai AM, Corbelli KS, Gabriel E, Kurtz DM, Khodadoust MS, Gupta NK, Maeda LS, Advani RH, Alizadeh AA, Levy R. CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity. Blood Cancer Discov. 2022 Mar 1;3(2):95-102. doi: 10.1158/2643-3230.BCD-21-0222. PMID: 35015688; PMCID: PMC9610898.
• Mooney KL, Czerwinski DK, Shree T, Frank MJ, Haebe S, Martin BA, Testa S, Levy R, Long SR. Serial FNA allows direct sampling of malignant and infiltrating immune cells in patients with B-cell lymphoma receiving immunotherapy. Cancer Cytopathol. 2022 Mar;130(3):231-237. doi: 10.1002/cncy.22531. Epub 2021 Nov 15. PMID: 34780125; PMCID: PMC8897258.
• Sagiv-Barfi I, Czerwinski DK, Shree T, Lohmeyer JJK, Levy R. Intratumoral immunotherapy relies on B and T cell collaboration. Sci Immunol. 2022 May 27;7(71):eabn5859. doi: 10.1126/sciimmunol.abn5859. Epub ahead of print. PMID: 35622903; PMCID: PMC9254330.
• Shree T. Can B cell-deficient patients rely on COVID-19 vaccine-induced T-cell immunity? Br J Haematol. 2022 Jun;197(6):659-661. doi: 10.1111/bjh.18210. Epub 2022 Apr 25. PMID: 35412649; PMCID: PMC9111762.
• Mentz M, Keay W, Strobl CD, Antoniolli M, Adolph L, Heide M, Lechner A, Haebe S, Osterode E, Kridel R, Ziegenhain C, Wange LE, Hildebrand JA, Shree T, Silkenstedt E, Staiger AM, Ott G, Horn H, Szczepanowski M, Richter J, Levy R, Rosenwald A, Enard W, Zimber-Strobl U, von Bergwelt-Baildon M, Hiddemann W, Klapper W, Schmidt-Supprian M, Rudelius M, et al. PARP14 is a novel target in STAT6 mutant follicular lymphoma. Leukemia. 2022 Sep;36(9):2281-2292. doi: 10.1038/s41375-022-01641-x. Epub 2022 Jul 18. PMID: 35851155; PMCID: PMC9417990.
• Grimes SM, Kim HS, Roy S, Sathe A, Ayala CI, Bai X, Almeda-Notestine AF, Haebe S, Shree T, Levy R, Lau BT, Ji HP. Single-cell multi-gene identification of somatic mutations and gene rearrangements in cancer. NAR Cancer. 2023 Jul 10;5(3):zcad034. doi: 10.1093/narcan/zcad034. PMID: 37435532; PMCID: PMC10331933.
• Haebe S, Day G, Czerwinski DK, Sathe A, Grimes SM, Chen T, Long SR, Martin B, Ozawa MG, Ji HP, Shree T, Levy R. Follicular lymphoma evolves with a surmountable dependency on acquired glycosylation motifs in the B-cell receptor. Blood. 2023 Dec 28;142(26):2296-2304. doi: 10.1182/blood.2023020360. PMID: 37683139; PMCID: PMC10797552.
• Shree T, Haebe S, Czerwinski DK, Eckhert E, Day G, Sathe A, Grimes S, Frank MJ, Maeda LS, Alizadeh AA, Advani R, Hoppe RT, Long SR, Martin B, Ozawa MG, Khodadoust MS, Ji HP, Levy R. A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single-cell analysis. Blood Adv. 2024 Jan 9;8(1):130-142. doi: 10.1182/bloodadvances.2023011589. PMID: 37939259; PMCID: PMC10787245.
• Spinner MA, Ker JP, Stoudenmire CJ, Fadare O, Mace EM, Orange JS, Hsu AP, Holland SM. GATA2 deficiency underlying severe blastomycosis and fatal herpes simplex virus-associated hemophagocytic lymphohistiocytosis. J Allergy Clin Immunol. 2016 Feb;137(2):638-40. doi: 10.1016/j.jaci.2015.07.043. Epub 2015 Sep 26. PMID: 26395816; PMCID: PMC4747814.
• Spinner MA, Fernandez-Vina M, Creary LE, Quinn O, Elder L, Arai S, Johnston LJ, Meyer EH, Miklos DB, Muffly LS, Negrin RS, Shizuru JA, Weng WK, Laport GG, Strober S, Lowsky R, Rezvani AR. HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. Blood Adv. 2017 Jul 25;1(17):1347-1357. doi: 10.1182/bloodadvances.2017007716. PMID: 29296777; PMCID: PMC5727975.
• Spinner MA, Advani RH, Connors JM, Azzi J, Diefenbach C. New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little? Am Soc Clin Oncol Educ Book. 2018 May 23;38:626-636. doi: 10.1200/EDBK_200679. PMID: 30231319.
• Spinner MA, Advani RH, Hoppe RT, Lowsky R, Muffly LS. Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation. Blood Adv. 2018 Jul 10;2(13):1547-1550. doi: 10.1182/bloodadvances.2018021071. PMID: 29970391; PMCID: PMC6039652.
• Spinner MA, Varma G, Advani RH. Novel Approaches in Waldenström Macroglobulinemia. Hematol Oncol Clin North Am. 2018 Oct;32(5):875-890. doi: 10.1016/j.hoc.2018.05.014. Epub 2018 Jul 19. PMID: 30190025.
• Spinner MA, Advani RH. Risk-adapted therapy for advanced-stage Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):200-206. doi: 10.1182/asheducation-2018.1.200. PMID: 30504311; PMCID: PMC6245987.
• Spinner MA, Varma G, Advani RH. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol. 2019 Jan;184(1):17-29. doi: 10.1111/bjh.15616. Epub 2018 Nov 28. PMID: 30485408.
• Lin JK, Muffly LS, Spinner MA, Barnes JI, Owens DK, Goldhaber-Fiebert JD. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma. J Clin Oncol. 2019 Aug 20;37(24):2105-2119. doi: 10.1200/JCO.18.02079. Epub 2019 Jun 3. PMID: 31157579.
• Spinner MA, Kennedy VE, Tamaresis JS, Lavori PW, Arai S, Johnston LJ, Meyer EH, Miklos DB, Muffly LS, Negrin RS, Rezvani AR, Shizuru JA, Weng WK, Hoppe RT, Strober S, Lowsky R. Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. Blood Adv. 2019 Aug 27;3(16):2454-2464. doi: 10.1182/bloodadvances.2019000297. PMID: 31427277; PMCID: PMC6712526.
• Merryman RW, Carreau NA, Advani RH, Spinner MA, Herrera AF, Chen R, Tomassetti S, Ramchandren R, Hamid M, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David KA, Wei C, Lansigan F, Emery L, Persky D, Smith SM, Godfrey J, Chavez J, et al. Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. Oncologist. 2020 Jun;25(6):e993-e997. doi: 10.1634/theoncologist.2020-0040. Epub 2020 Apr 28. PMID: 32275786; PMCID: PMC7288660.
• Spinner MA, Aleshin A, Santaguida MT, Schaffert SA, Zehnder JL, Patterson AS, Gekas C, Heiser D, Greenberg PL. Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms. Blood Adv. 2020 Jun 23;4(12):2768-2778. doi: 10.1182/bloodadvances.2020001934. PMID: 32569379; PMCID: PMC7322964.
• Carreau NA, Pail O, Armand P, Merryman R, Advani RH, Spinner MA, Herrera A, Chen R, Tomassetti S, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair S, Barta S, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David K, Wei C, Lansigan F, Emery L, Persky D, Smith S, et al. Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. Oncologist. 2020 Oct;25(10):878-885. doi: 10.1634/theoncologist.2020-0167. Epub 2020 Aug 28. PMID: 32720734; PMCID: PMC7543382.
• Carreau NA, Armand P, Merryman RW, Advani RH, Spinner MA, Herrera AF, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Nathan S, Karmali R, Torka P, David K, Lansigan F, Persky D, Godfrey J, Chavez JC, Xia Y, Diefenbach C. Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. Br J Haematol. 2020 Oct;191(1):44-51. doi: 10.1111/bjh.16756. Epub 2020 May 19. PMID: 32430944.
• Ghione P, Faruque P, Mehta-Shah N, Seshan V, Ozkaya N, Bhaskar S, Yeung J, Spinner MA, Lunning M, Inghirami G, Moskowitz A, Galasso N, Ganesan N, van der Weyden C, Ruan J, Prince HM, Trotman J, Advani R, Dogan A, Horwitz S. T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma. Blood Adv. 2020 Oct 13;4(19):4640-4647. doi: 10.1182/bloodadvances.2020002396. PMID: 33002132; PMCID: PMC7556143.
• Merryman RW, Redd RA, Nishihori T, Chavez J, Nieto Y, Darrah JM, Rao U, Byrne MT, Bond DA, Maddocks KJ, Spinner MA, Advani RH, Ballard HJ, Svoboda J, Singh AK, McGuirk JP, Modi D, Ramchandren R, Romancik J, Cohen JB, Frigault MJ, Chen YB, Serritella AV, Kline J, Ansell S, Nathan S, Rahimian M, Joyce RM, Shah M, et al. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv. 2021 Mar 23;5(6):1648-1659. doi: 10.1182/bloodadvances.2020003556. PMID: 33710337; PMCID: PMC7993097.
• Menke JR, Spinner MA, Natkunam Y, Warnke RA, Advani RH, Gratzinger DA. CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center. Arch Pathol Lab Med. 2021 Jun 1;145(6):753-758. doi: 10.5858/arpa.2020-0135-OA. PMID: 32991677.
• Advani RH, Skrypets T, Civallero M, Spinner MA, Manni M, Kim WS, Shustov AR, Horwitz SM, Hitz F, Cabrera ME, Dlouhy I, Vassallo J, Pileri SA, Inghirami G, Montoto S, Vitolo U, Radford J, Vose JM, Federico M. Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project. Blood. 2021 Jul 22;138(3):213-220. doi: 10.1182/blood.2020010387. PMID: 34292324; PMCID: PMC8493974.
• Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, Casadei B, Bond DA, Jaglowski S, Spinner MA, Arai S, Lowsky R, Shah GL, Perales MA, De Colella JMS, Blaise D, Herrera AF, Shouse G, Spilleboudt C, Ansell SM, Nieto Y, Badar T, Hamadani M, Feldman TA, Dahncke L, Singh AK, McGuirk JP, Nishihori T, Chavez J, et al. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021 Sep;35(9):2672-2683. doi: 10.1038/s41375-021-01193-6. Epub 2021 Mar 3. PMID: 33658659.
• Marciano BE, Olivier KN, Folio LR, Zerbe CS, Hsu AP, Freeman AF, Filie AC, Spinner MA, Sanchez LA, Lovell JP, Parta M, Cuellar-Rodriguez JM, Hickstein DD, Holland SM. Pulmonary Manifestations of GATA2 Deficiency. Chest. 2021 Oct;160(4):1350-1359. doi: 10.1016/j.chest.2021.05.046. Epub 2021 Jun 3. PMID: 34089740; PMCID: PMC8546236.
• Brar N, Spinner MA, Baker MC, Advani RH, Natkunam Y, Lewis DB, Silva O. Increased double-negative αβ+ T-cells reveal adult-onset autoimmune lymphoproliferative syndrome in a patient with IgG4-related disease. Haematologica. 2022 Jan 1;107(1):347-350. doi: 10.3324/haematol.2021.279297. PMID: 34474549; PMCID: PMC8719087.
• Spinner MA, Advani RH. Current Frontline Treatment of Diffuse Large B-Cell Lymphoma. Oncology (Williston Park). 2022 Jan 20;36(1):51-58. doi: 10.46883/2022.25920940. PMID: 35089671.
• Orellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins M, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers A, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski A, Ayers EC, Landsburg DJ, Echalier B, Lee J, et al. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2022 Jan 20;139(3):413-423. doi: 10.1182/blood.2021012888. PMID: 34570876; PMCID: PMC8777199.
• Hamid MS, Rutherford SC, Jang H, Kim S, Patel K, Bartlett NL, Malecek MK, Watkins MP, Maddocks KJ, Bond DA, Feldman TA, Magarelli G, Advani RH, Spinner MA, Evens AM, Shah M, Ahmed S, Stephens DM, Allen P, Tees MT, Karmali R, Cheson BD, Yazdy MS, Strouse C, Bailey NA, Pagel JM, Ramchandren R. Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience. Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):e435-e442. doi: 10.1016/j.clml.2021.12.012. Epub 2021 Dec 25. PMID: 35093285.
• Desai SH, Spinner MA, David K, Bachanova V, Goyal G, Kahl B, Dorritie K, Azzi J, Kenkre VP, Arai S, Chang C, Fusco B, Sumransub N, Hatic H, Saba R, Ibrahim U, Harris EI, Shah H, Murphy J, Ansell S, Jagadish D, Orellana-Noia V, Diefenbach C, Iyenger S, Rappazzo KC, Mishra R, Choi Y, Nowakowski GS, Advani RH, et al. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma. Am J Hematol. 2023 Mar;98(3):464-471. doi: 10.1002/ajh.26827. Epub 2023 Jan 11. PMID: 36629030.
• Spinner MA, Sica RA, Tamaresis JS, Lu Y, Chang C, Lowsky R, Frank MJ, Johnston LJ, Miklos DB, Muffly LS, Negrin RS, Rezvani AR, Shiraz P, Shizuru JA, Weng WK, Binkley MS, Hoppe RT, Advani RH, Arai S. Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents. Blood. 2023 Jun 1;141(22):2727-2737. doi: 10.1182/blood.2022018827. PMID: 36857637.
• Bowers JT, Anna JL, Bair SM, Annunzio K, Epperla N, Joy Pullukkara J, Gaballa S, Spinner MA, Li S, Messmer MR, Nguyen JDK, Ayers EC, Wagner C, Hu B, Di M, Huntington SF, Furqan F, Shah NN, Chen C, Ballard HJ, Hughes ME, Chong EA, Nasta SD, Barta SK, Landsburg DJ, Svoboda J. Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort. Blood Adv. 2023 Aug 18:10.1182/bloodadvances.2023010622. doi: 10.1182/bloodadvances.2023010622. Epub ahead of print. PMID: 37595053.
• Desai SH, Spinner MA, Evens AM, Sykorova A, Bachanova V, Goyal G, Kahl B, Dorritie K, Azzi J, Kenkre VP, Chang C, Michalka J, Ansell SM, Fusco B, Sumransub N, Hatic H, Saba R, Ibrahim U, Harris EI, Shah H, Wagner-Johnston N, Arai S, Nowakowski GS, Mocikova H, Jagadeesh D, Blum KA, Diefenbach C, Iyengar S, Rappazzo KC, et al. Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era. Blood Adv. 2023 Dec 12;7(23):7295-7303. doi: 10.1182/bloodadvances.2023011205. PMID: 37729621; PMCID: PMC10711178.
• Khanna V, Lu R, Kumar J, Molina A, Stehr H, Spiteri E, Spinner M, Silva O, Fernandez-Pol S, Tan B, Greenberg PL. The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms. Leuk Res. 2024 Jan;136:107433. doi: 10.1016/j.leukres.2023.107433. Epub 2023 Dec 19. PMID: 38154193.
• Spinner MA, Advani RH. Emerging immunotherapies in the Hodgkin lymphoma armamentarium. Expert Opin Emerg Drugs. 2024 May 6:10.1080/14728214.2024.2349083. doi: 10.1080/14728214.2024.2349083. Epub ahead of print. PMID: 38676917.
• Chang YS, Huang K, Lee JM, Vagts CL, Ascoli C, Amin MR, Ghassemi M, Lora CM, Edafetanure-Ibeh R, Huang Y, Cherian RA, Sarup N, Warpecha SR, Hwang S, Goel R, Turturice BA, Schott C, Hernandez M, Chen Y, Joregensen J, Wang W, Rasic M, Novak RM, Finn PW, Perkins DL. Immune response to the mRNA COVID-19 vaccine in hemodialysis patients: cohort study. medRxiv. 2023 Jan 19:10.1101/2023.01.19.23284792. doi: 10.1101/2023.01.19.23284792. PMID: 36711520; PMCID: PMC9882629.
• Chang YS, Huang K, Lee JM, Vagts CL, Ascoli C, Amin MR, Ghassemi M, Lora CM, Edafetanure-Ibeh R, Huang Y, Cherian RA, Sarup N, Warpecha SR, Hwang S, Goel R, Turturice BA, Schott C, Hernandez M, Chen Y, Jorgensen J, Wang W, Rasic M, Novak RM, Finn PW, Perkins DL. Altered transcriptomic immune responses of maintenance hemodialysis patients to the COVID-19 mRNA vaccine. Elife. 2024 Apr 24;13:10.7554/eLife.83641. doi: 10.7554/eLife.83641. PMID: 38656290; PMCID: PMC11042800.